Home BreakingSymbiomics and Valeouro forge strategic partnership to advance genome editing in the biologicals sector

Symbiomics and Valeouro forge strategic partnership to advance genome editing in the biologicals sector

by Joseph Wilson
5 minutes read

The partnership combines Symbiomics’ proprietary platform with Valeouro’s expertise in developing and launching innovative technologies to accelerate the delivery of new biological solutions to farmers

Against the backdrop of growing demand for innovation in agricultural biologicals, biotechnology companies Symbiomics and Valeouro Biotec have announced a strategic partnership to develop a new generation of solutions for disease management in Brazil’s main agricultural systems.

Under the alliance, Symbiomics and Valeouro Biotec will work together: Symbiomics will contribute its proprietary microorganism discovery and genome-editing platform, while Valeouro will bring its extensive knowledge of Brazilian agriculture, connecting strategic market-access, technical and industrial capabilities. The companies expect the new generation of solutions to reach the market within the next two to three years.

The partnership comes at a time of expansion in Brazil’s biologicals market. According to CropLife Brasil, an association representing companies specializing in the research and development of solutions for sustainable agricultural production, the sector generated R$6.2 billion in 2025, a 15% increase from the previous year. Over the same period, the area treated with biological products grew 28%, reaching 194 million hectares.

Soybeans, corn and sugarcane together account for more than 90% of the use of these technologies in the country. Biocontrol segments (bioinsecticides, bionematicides and biofungicides) accounted for most of the sector’s revenue, totaling approximately R$5.4 billion in 2025.

As biological products become more established in agriculture, demand is also growing for new technologies capable of improving their performance, consistency and differentiation. Brazil already has more than 700 registered products, underscoring the expansion and importance of this market. The sector’s next leap, however, will depend not only on launching new products, but also on incorporating tools that enable the development of solutions with superior characteristics and clearer benefits for growers.

In this context, genome editing emerges as a promising alternative. By enabling the precise enhancement of traits in microorganisms of agricultural interest, this technology has the potential to increase their robustness, efficiency, and stability, as well as ensure more consistent performance under different soil and climatic conditions. It also has the potential to accelerate the development of products that differentiate themselves from those already available on the market, going beyond the incremental gains that characterize conventional approaches.

“To develop a product that truly differentiates itself from what is already available on the market, it is necessary to expand the diversity of microorganisms explored and use technologies capable of enhancing their characteristics,” says Rafael de Souza, CEO and co-founder of Symbiomics. “Symbiomics has a proprietary collection of thousands of isolated microorganisms and combines microbiome and genome-editing technologies to develop high-performance biological products based on more robust microorganisms for biocontrol. Our goal is to turn this capability into a product with clear differentiators and consistent field performance that contributes to growers’ productivity and profitability. I see Valeouro as the ideal structure and the right partner to scale this technology and bring it to growers,” he adds.

Founded in 2021, Valeouro has built a diversified and robust portfolio in just a few years, with more than 20 products currently marketed in Brazil. With innovation at the core of its strategy, the company has been expanding its investments in research and development, with support from Finep, to increase the technological sophistication of its portfolio and accelerate the launch of new products into the market.

“Our biomanufacturing facility, scheduled to begin operations in the coming years, was designed to provide the industrial capacity required to scale up and manufacture new technologies. The facility will enable us to take disruptive products from the development stage to industrial scale, as exemplified by what is emerging from our alliance with Symbiomics, strengthening the synergy between the two companies,” says Luciano Galera, CEO of Valeouro Biotec.

In addition to the technology’s differentiating capabilities, the partnership was structured to reduce the time between the discovery of a microorganism and its transformation into a product. “In biologicals, gaining speed does not mean eliminating steps, but making better decisions earlier. To achieve this, over the past five years Symbiomics has implemented a proprietary platform that integrates the latest advances in microbiome studies, genomic sequencing, machine learning and genome editing. This structure allows us to select and improve microorganisms with greater precision, increasing the chances of developing high-performance products in shorter cycles than conventional development processes. In this regard, Valeouro’s participation brings an industrial perspective from the outset and shortens the path from technology to market,” explains Jader Armanhi, COO and co-founder of Symbiomics.

The expectation is that the technology will be integrated into disease management programs, with the potential to sustainably increase productivity while reducing operating costs per hectare. “More than developing a new product, we want to transform scientific innovation into a solution that delivers performance, consistency, and value to growers. This is our vision for the future: to contribute to building a new generation of biological products that are more efficient, competitive, and capable of generating a real impact in the field,” says Flávia Camargo, Executive Manager of Research, Development, and Innovation at Valeouro Biotec.

About Symbiomics

Symbiomics is a Brazilian biotechnology company. Founded in 2021, its goal is to transform agriculture globally through next-generation biological products. The company develops high-performance solutions to increase agricultural productivity sustainably and with lower environmental impact. Its products contain robust microorganisms used for multiple applications, including plant nutrition, biocontrol, carbon sequestration and biostimulants. The company’s Research & Development team works with the most advanced technologies in genomics, microbiome science and data analysis to increase crop productivity through approaches such as biofertilization, enhanced resilience to environmental stresses and biological control.

About Valeouro Biotec

A Valeouro Biotec é uma empresa brasileira de biotecnologia dedicada ao desenvolvimento de biossoluções para uma agricultura mais produtiva, eficiente e sustentável. Com sede em Ribeirão Preto (SP), a companhia atua no desenvolvimento e comercialização de produtos biológicos para diferentes desafios do campo, incluindo nutrição vegetal, controle biológico de pragas e doenças, saúde do solo e bioativação.

Com a inovação no centro de sua estratégia, a Valeouro investe em Pesquisa, Desenvolvimento e Inovação e mantém parcerias com instituições de pesquisa e empresas de base tecnológica para ampliar e fortalecer seu portfólio. A companhia vem também expandindo sua capacidade industrial para acelerar o desenvolvimento, a produção e a chegada de novas tecnologias ao mercado.

By integrating science, technological development, market intelligence and knowledge of the agricultural market, Valeouro seeks to transform innovation into solutions with a real impact in the field and contribute to more efficient, sustainable and competitive Brazilian agriculture.

You may also like

A News Publication Company
CBHerald.com is your one-stop platform for breaking news and information. We are an online news company committed to providing accurate, dependable, and timely coverage of the events and issues that are most important to our readers.